Dayang Biotech Releases 2026 Interim Report with Net Profit of 57.4693 Million Yuan

Earnings
โดย Jiemian·Read original
Summary · why it matters

Dayang Biotech released its 2026 interim report, with net profit attributable to the parent company of 57.4693 million yuan. The company's total operating revenue was 559 million yuan, and net cash inflow from operating activities was 51.6258 million yuan, down 54.46% from the same period last year. The company's latest asset-liability ratio was 40.43%, gross margin was 23.02%, and diluted earnings per share was 0.59 yuan.

Impact on stocks 1

Others▲ · 1 stocks
© 2026 MarketDXNews